Cenix is equipped to do high-throughput, genome-scale RNAi screening. The firm believes that its infrastructure and expertise will allow it to help Big pharma and biotech partners sort through masses of targets to find those with biological relevance. Management believes its methodology can also contribute to drug development--RNAi could, for instance, act as a modifier in screening assays, to see whether this additional means of silencing a gene could improve a drug candidate's activity.
Pfotenhauerstrasse 108
D-01307 Dresden, Germany
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.
The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.
Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.
